Fracture healing with alendronate treatment in the Brtl/ plus mouse model of osteogenesis imperfecta

被引:19
|
作者
Meganck, J. A. [1 ,2 ]
Begun, D. L. [1 ,2 ]
McElderry, J. D. [3 ]
Swick, A. [1 ,2 ]
Kozloff, K. M. [1 ,2 ]
Goldstein, S. A. [1 ,2 ]
Morris, M. D. [3 ]
Marini, J. C. [4 ]
Caird, M. S. [1 ]
机构
[1] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
[4] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
Osteogenesis imperfecta; Bisphosphonates; Bone; Rodent; Fracture repair; HYPERPLASTIC CALLUS FORMATION; POLARIZED-LIGHT MICROSCOPY; ZOLEDRONIC ACID; BISPHOSPHONATE INCADRONATE; BONE STRENGTH; CHILDREN; PAMIDRONATE; COLLAGEN; REPAIR; RATS;
D O I
10.1016/j.bone.2013.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality. Acutely, there is concern about risk of non-union of fractures that occur near the time of bisphosphonate administration. This study investigated the effect of alendronate, a potent aminobisphosphonate, on fracture healing. Using the Brtl/+ murine model of type IV OI, tibial fractures were generated in 8-week-old mice that were untreated, treated with alendronate before fracture, or treated before and after fracture. After 2, 3, or 5 weeks of healing, tibiae were assessed using microcomputed tomography (mu CT), torsion testing, quantitative histomorphometry, and Raman microspectroscopy. There were no morphologic, biomechanical or histomorphometric differences in callus between untreated mice and mice that received alendronate before fracture. Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus. Both Brtl/+ and WT mice that received alendronate before and after fracture had increases in the callus volume, bone volume fraction and torque at failure after 5 weeks of healing. Raman microspectroscopy results did not show any effects of alendronate in wild-type mice, but calluses from Brtl+ mice treated with alendronate during healing had a decreased mineral-to-matrix ratio, decreased crystallinity and an increased carbonate-to-phosphate ratio. Treatment with alendronate altered the dynamics of healing by preventing callus volume decreases later in the healing process. Fracture healing in Brtl/+ untreated animals was not significantly different from animals in which alendronate was halted at the time of fracture. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [31] Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/ plus Osteogenesis Imperfecta Mouse Model
    Olvera, Diana
    Stolzenfeld, Rachel
    Marini, Joan C.
    Caird, Michelle S.
    Kozloff, Kenneth M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (07) : 1272 - 1282
  • [32] Successful treatment of severe osteogenesis imperfecta with oral alendronate
    Miller, ME
    Hangartner, TN
    PEDIATRIC RESEARCH, 2000, 47 (04) : 242A - 242A
  • [33] Osteogenesis imperfecta: Alendronate reduces fractures and corrects spinal curvature in infant mouse model
    McCarthy, EA
    Hossack, M
    Miller, EA
    Zraick, V
    Jain, M
    Boacci, O
    Raggio, C
    Camacho, NP
    PEDIATRIC RESEARCH, 2000, 47 (04) : 415A - 415A
  • [34] Alendronate Reduces Fractures and Corrects Spinal Curvature in Infant Mouse Model of Osteogenesis Imperfecta
    E A McCarthy
    M Hossack
    E A Miller
    C Raggio
    N P Camacho
    Pediatric Research, 1999, 45 : 210 - 210
  • [35] Alendronate reduces fractures and corrects spinal curvature in infant mouse model of osteogenesis imperfecta
    McCarthy, EA
    Hossack, M
    Miller, EA
    Raggio, C
    Camacho, NP
    PEDIATRIC RESEARCH, 1999, 45 (04) : 210A - 210A
  • [36] BONE FRACTURE TREATMENT IN OSTEOGENESIS IMPERFECTA
    SCHWEIKE.CH
    WESSINGH.D
    RAHMANZA.R
    MONATSSCHRIFT FUR UKNFALLHEILKUNDE VERISCHERUNGS-VERSORUNGS-UND VERKEHRSMEDIZIN, 1969, 72 (09): : 371 - &
  • [37] Increased cell surface TGF-β receptor on osteoblastic cells from Brtl mouse model for osteogenesis imperfecta.
    Chang, W.
    Nou, D.
    Marini, J.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S369 - S369
  • [38] The effect of alendronate on long bone growth and growth plate in the OIM mouse model for osteogenesis imperfecta
    Evans, KD
    Martin, RB
    Lau, ST
    Oberbauer, AM
    BONE, 2001, 28 (05) : S114 - S115
  • [39] Treatment of osteogenesis imperfecta type I with weekly alendronate.
    Gensure, RC
    Ponnapakkam, T
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S175 - S176
  • [40] Successful treatment of severe osteogenesis imperfecta with oral alendronate.
    Miller, ME
    Hangartner, TN
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 431 - 431